Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.

Objective: Evaluate the effects of α-difluoromethylornithine (DFMO) on hearing thresholds as part of a randomized, double-blind, placebo-controlled trial.

Methods: Subjects were randomized and assigned to the control (placebo) or experimental (DFMO) group. DFMO or placebo were administered orally (500 mg/m /day) for up to 5 years.